NEW YORK – Natera and MyOme on Monday announced that they have partnered to launch a cross-ancestry, integrated polygenic risk score (iPRS) for five-year and lifetime breast cancer risk.
The iPRS, published last year in JCO Precision Oncology, integrates the effects of over 1 million single nucleotide polymorphisms (SNPs) from whole-genome sequencing with the standard Tyrer-Cuzick (T-C) model clinical inputs from a patient's medical history and will be offered as a further risk assessment to individuals who receive a negative test result with Natera's Empower hereditary cancer test. The test is available to individuals between 18 and 85 years of age without personal histories of breast cancer and no mutations in a known breast cancer-related gene.
Financial and other details of the collaboration were not disclosed.
"iPRS addresses a critical need for a cross-ancestry polygenic risk score based on genetic, rather than self-reported, ancestry," Ramesh Hariharan, general manager of women's health at Natera, said in a statement.
"Our integrated PRS score — the first of many clinically impactful models that will change proactive health — has been thoroughly validated across ancestries and provides a highly accurate risk assessment that enables physicians to construct a personalized screening program to help detect breast cancer in its earliest, most treatable stages," added Akash Kumar, chief medical and science officer at MyOme.